---
document_datetime: 2023-09-21 20:49:34
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/lenalidomide-krka-dd-novo-mesto-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: lenalidomide-krka-dd-novo-mesto-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.3594882
conversion_datetime: 2025-12-20 19:10:30.986748
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

## Lenalidomide Krka d.d. Novo mesto

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                          | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0004              | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation | 13/12/2021                          |                                             | SmPC, Labelling and PL           |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IB/0003   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                  | 12/10/2021   |     | SmPC                             |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-----|----------------------------------|
| IAIN/0002 | A.2.a - Administrative change - Change in the (invented) name of the medicinal product for CAPs                                                            | 04/08/2021   |     | SmPC, Annex II, Labelling and PL |
| IA/0001   | B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size | 07/05/2021   | n/a |                                  |